Trial · NCT04006457
Adverse events368
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 368
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | GASTROINTESTINAL DISORDERS | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | 24 | 447 | |
| other | Diarrhoea | GASTROINTESTINAL DISORDERS | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | 25 | 603 | |
| other | Diarrhoea | GASTROINTESTINAL DISORDERS | Vaccine Sub-study: Tdap Vaccination | 0 | 17 | |
| other | Diarrhoea | GASTROINTESTINAL DISORDERS | Vaccine Sub-study: Meningococcal ACWY Vaccination | 0 | 13 | |
| other | Gastrooesophageal reflux disease | GASTROINTESTINAL DISORDERS | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | 0 | 447 | |
| other | Gastrooesophageal reflux disease | GASTROINTESTINAL DISORDERS | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | 0 | 603 | |
| other | Gastrooesophageal reflux disease | GASTROINTESTINAL DISORDERS | Vaccine Sub-study: Tdap Vaccination | 1 | 17 | |
| other | Gastrooesophageal reflux disease | GASTROINTESTINAL DISORDERS | Vaccine Sub-study: Meningococcal ACWY Vaccination | 0 | 13 | |
| other | Nausea | GASTROINTESTINAL DISORDERS | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | 27 | 447 | |
| other | Nausea | GASTROINTESTINAL DISORDERS | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | 27 | 603 | |
| other | Nausea | GASTROINTESTINAL DISORDERS | Vaccine Sub-study: Tdap Vaccination | 0 | 17 | |
| other | Nausea | GASTROINTESTINAL DISORDERS | Vaccine Sub-study: Meningococcal ACWY Vaccination | 0 | 13 | |
| other | Fatigue | GENERAL DISORDERS | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | 47 | 447 | |
| other | Fatigue | GENERAL DISORDERS | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | 41 | 603 | |
| other | Fatigue | GENERAL DISORDERS | Vaccine Sub-study: Tdap Vaccination | 0 | 17 | |
| other | Fatigue | GENERAL DISORDERS | Vaccine Sub-study: Meningococcal ACWY Vaccination | 0 | 13 | |
| other | Pyrexia | GENERAL DISORDERS | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | 59 | 447 | |
| other | Pyrexia | GENERAL DISORDERS | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | 64 | 603 | |
| other | Pyrexia | GENERAL DISORDERS | Vaccine Sub-study: Tdap Vaccination | 0 | 17 | |
| other | Pyrexia | GENERAL DISORDERS | Vaccine Sub-study: Meningococcal ACWY Vaccination | 0 | 13 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04006457/events